ACE and hypertensive disorder: However, the Diabetes Reduction Assessment with Ramipril and Rosiglitazone Medication (DREAM) trial failed to show a statistically significant reduction in NOD with the ACE inhibitor ramipril versus placebo in patients with impaired fasting glucose.29 The lack of hypertension as an inclusion criterion and the relatively short follow-up period (3 years) in the DREAM trial might explain why no significant differences in NOD were detected between the 2 groups.